Total item
Cart Subtotal
$0.00 - Koide H, .et al. Substrate-dependent effects of molecular-targeted anticancer agents on activity of organic anion transporting polypeptide 1B1, Xenobiotica, 2018, Oct;48(10):1059-1071 PMID: 29034773
- Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
- Tomoko Ogawa-Morita, .et al. Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma, Int J Anal Chem, 2017, 2017: 2341876 PMID: 28680445
Biological Activity
E7080 is a multi-kinase inhibitor that inhibits both VEGFR2 and VEGFR3 kinases.
Targets
| Target | Value |
|---|---|
| VEGFR2/KDR | IC50: 4.0nM |
| VEGFR3/FLT4 | IC50: 5.2nM |
| VEGFR1/FLT1 | IC50: 22nM |
| PDGFRβ | IC50: 39nM |
| FGFR1 | IC50: 46nM |
| PDGFRα | IC50: 51nM |
| Kit | IC50: 100nM |
| EphB4 | IC50: >10μM |
| IGF-1R | IC50: >10μM |
| Insulin Receptor | IC50: >10μM |
| Src | IC50: >10μM |
| Akt1 | IC50: >10μM |
| CDK4/CyclinD | IC50: >10μM |
| PLK1 | IC50: >10μM |
| FAK | IC50: >10μM |
| PKCα | IC50: >10μM |
| In vitro (25°C) | DMSO | Warmed: 35 mg/mL (81.99 mM) | |
| Water | Insoluble | ||
| Ethanol | Insoluble | ||
| In vivo | 0.5% methylcellulose | 28 mg/mL | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 23.42 mL | 117.12 mL | 234.25 mL |
| 0.5 mM | 4.68 mL | 23.42 mL | 46.85 mL |
| 1 mM | 2.34 mL | 11.71 mL | 23.42 mL |
| 5 mM | 0.47 mL | 2.34 mL | 4.68 mL |
*The above data is based on the productmolecular weight 426.9. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Catalog Num | A10340 |
|---|---|
| Actions | Inhibitor |
| CAS No. | 417716-92-8 |
| Formula | C21H19ClN4O4 |
| M. Wt | 426.9 |
| Purity | >98% |
| Synonyms | E-7080 |
| SMILES | COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl |
| Storage | Store lyophilized at -20ºC, keep desiccated. |
Datasheet
Product Tags
Product Questions
Product Questions
No Questions
You may also be interested in the following product(s)
SU 5416 (Semaxinib)
SU 5416 is an inhibitor of vascular endothelial growth factor receptor (VEGFR) that also inhibits other tyrosine kinases KIT, MET, FLT3 and …
Regorafenib (BAY 73-4506)
Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an ora…
Taxifolin
Taxifolin is found to bind at the ATP-binding site on VEGFR-2 kinase with large value of binding energy and act as type I competitive inhibi…
Ki8751
Ki8751 is a cell-permeable quinolyloxyphenyl-urea compound that acts as a Flk-1 (VEGFR-2)-selective inhibitior in both cell-based and cell-f…
TG 100572
TG 100572 is VEGFR2 and Src kinase inhibitor.
Tivozanib (AV-951)
Tivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor that is designed to inhibit all three VEGF receptors.
(-)-Catechin gallate
(-)-Catechin gallate is an antioxidant constituent of green tea. At uM concentrations, inhibits VEGF-induced tyrosine phosphorylation.
XL647 (Tesevatinib)
XL647 is an orally bioavailable small-molecule RTK inhibitor that binds to and inhibits several tyrosine receptor kinases that play major ro…
Keywords:buy E7080 (Lenvatinib) | E7080 (Lenvatinib) Supplier | purchase | cost | manufacturer | order | distributor | buy 417716-92-8| 417716-92-8 Supplier | purchase 417716-92-8 | 417716-92-8 cost | 417716-92-8 manufacturer | order 417716-92-8 | 417716-92-8 distributor
Adooq Quality Guarantee
We promise all products perform as described.